GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » Capex-to-Operating-Cash-Flow

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Capex-to-Operating-Cash-Flow : 0.22 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

ExpreS2ion Biotech Holding AB's Capital Expenditure for the three months ended in Mar. 2024 was kr-0.19 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was kr0.85 Mil.

Hence, ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 0.22.


ExpreS2ion Biotech Holding AB Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB Capex-to-Operating-Cash-Flow Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ExpreS2ion Biotech Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.22

Competitive Comparison of ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow falls into.



ExpreS2ion Biotech Holding AB Capex-to-Operating-Cash-Flow Calculation

ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2.015) / -100.887
=N/A

ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.189) / 0.854
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


ExpreS2ion Biotech Holding AB Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Traded in Other Exchanges
Address
c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines